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Background: Although several systematic reviews investigated the safety of long-acting beta–agonists (LABAs) in
asthma, they mainly addressed randomized clinical trials while evidence from non-randomized studies has been
mostly neglected. We aim to assess the risk of serious adverse events in adults and children with asthma treated
with LABAs and Inhaled Corticosteroids (ICs), compared to patients treated only with ICs, from published
non-randomized studies.
Methods: The protocol registration number was CRD42012003387 (http://www.crd.york.ac.uk/Prospero). Literature
search for articles published since 1990 was performed in MEDLINE and EMBASE. Two authors selected studies
independently for inclusion and extracted the data. A third reviewer resolved discrepancies. To assess the risk of
serious adverse events, meta-analyses were performed calculating odds ratio summary estimators using random
effect models when heterogeneity was found, and fixed effect models otherwise.
Results: Of 4,415 candidate articles, 1,759 abstracts were reviewed and 220 articles were fully read. Finally, 19
studies met the inclusion criteria. Most of them were retrospective observational cohorts. Sample sizes varied from
50 to 514,216. The meta-analyses performed (69,939-624,303 participants according to the outcome considered)
showed that odds ratio of the LABAs and ICs combined treatment when compared with ICs alone was: 0.88 (95%
CI 0.69-1.12) for asthma-related hospitalization; 0.75 (95% CI 0.66-0.84) for asthma-related emergency visits; 1.02
(95% CI 0.94-1.10) for systemic corticosteroids; and 0.95 (95% CI 0.9-1.0) for the combined outcome.
Conclusions: Evidence from observational studies shows that the combined treatment of LABAs and ICs is not
associated with a higher risk of serious adverse events, compared to ICs alone. Major gaps identified were
prospective design, paediatric population and inclusion of mortality as a primary outcome.
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Long-Acting Beta-Agonists (LABAs) -salmeterol and
formoterol- were introduced in the ‘90s when they dem-
onstrated reducing symptoms and use of rescue medica-
tion [1]. Concerns about their safety appeared in 1993
when Castle et al. reported a threefold mortality in a ran-
domized clinical trial (RCT) comparing LABAs with* Correspondence: mferrer@imim.es
1Health Services Research Group. IMIM (Hospital del Mar Medical Research
Institute), Barcelona Biomedical Research Park, office 144. Doctor Aiguader,
88 | 08003, Barcelona, Spain
2Universitat Autònoma de Barcelona, Bellaterra, Spain
Full list of author information is available at the end of the article
© 2014 Hernández et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.SABAs [2]. Post-marketing reports of adverse events
showed an increased risk of death and serious asthma
events [3]. The Salmeterol Multicenter Asthma Research
Trial was stopped in 2003 after an interim analysis showed
a fourfold increased mortality amongst patients random-
ized to salmeterol vs. placebo [4]. Similar concerns about
formoterol were raised by a reanalysis of three RCTs.
Meta-analyses of RCTs with LABAs as a monotherapy in-
dicated an increased mortality risk [5,6].
Meta-analyses of RCTs examining the safety of LABAs
in combination with inhaled corticosteroids (ICs) showed
inconsistent results. Most of them found no significanttral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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related mortality compared with patients treated with ICs
alone [7-11]. But a statistically significant increase of cata-
strophic asthma events for LABAs plus ICs was shown by
the update of a meta-analysis [12]. In 2010, the Federal
Drug Administration (FDA) required label changes to in-
dicate contraindication of use of LABAs without concomi-
tant ICs, recommending only fixed-dose LABAs plus ICs
combination, and calling for new studies to address this
issue [13].
Nevertheless, there is still a lack of knowledge regard-
ing LABAs’ safety with concomitant ICs use, with both
theoretical arguments and limited empirical evidence
that ICs may mitigate LABA-associated risks [14-16].
Most of the systematic reviews currently available are
based on RCTs, which may present limitations to assess
long-term and rare outcomes [5,8-11]. Moreover, RCTs
may not reflect the actual patterns of use of these medi-
cations in asthma patients’ day-to-day regarding treat-
ment duration and adherence. To our knowledge, there
is only one systematic review of observational studies
[17]. Its meta-analysis showed that the combined treat-
ment was associated with a lower risk of asthma-related
hospitalizations and/or emergency room visits.
Since year 2008, end date of the above mentioned review,
many non-randomized studies have been published, espe-
cially due to the FDA’s 2010 call for further evidence. The
aim of this study was to assess the risk of serious adverse
events in patients with asthma treated with LABAs and
ICs in comparison to patients treated only with ICs, by
synthesizing the available evidence from non-randomized
studies through systematic review and meta-analysis.
Methods
The protocol registration number was CRD42012003387
(http://www.crd.york.ac.uk/Prospero). We searched MED-
LINE and EMBASE databases with a specific strategy (see
Additional file 1) from 1990, when LABAs were commer-
cialized, to January 20th, 2013.
We looked for non-randomized studies in all lan-
guages (non-randomized controlled trials, controlled
before-after studies, prospective or retrospective cohorts,
case-control studies) on adults, adolescents or children
with asthma diagnosis. Studies assessing treatment with
LABAs plus ICs (either as two separate inhalers or as a
single inhaler) compared with ICs monotherapy were
considered, regardless of the dose (see Additional file 1).
Co-therapy such as immunomodulators and leukotriene
modifiers were not excluded. We defined ‘severe exacerba-
tion’ following the American Thoracic Society/European
Respiratory Society statement [18] which was based on ur-
gent health care utilization: asthma-related emergency
department (ED) visits, hospitalizations, intubations, in-
tensive care unit (ICU) admissions, and use of systemiccorticosteroids were considered either specific or com-
bined outcomes.
Two members of the study team, a physician (GH)
and a pharmacist (MA), independently reviewed studies
found in the literature search by examining titles, ab-
stracts, and full text articles. A third reviewer (MF) re-
solved discrepancies. A pilot test was performed to
homogenize criteria among reviewers. Finally, the se-
lected articles’ reference lists were reviewed to identify
other possible studies that could be included.
Data were extracted by agreement of two reviewers
using a standardized, predefined data collection form,
including: study and participants characteristics, inter-
ventions, comparator, outcomes, asthma severity, co-
medication, and ethics consideration of each study.
Authors were contacted if clarification was needed.
The risk of bias in the identified studies was assessed
using a checklist developed by members of the Cochrane
Non-Randomised Studies Methods group [19]. We
assessed 4 categories of potential biases: groups of com-
parison, reasons for allocation in groups, parts of the
study that were prospective, and group comparability
(Additional file 1).
Analytic strategy
Reported adjusted OR and 95% confidence intervals
(95% CI) for the comparison of ICs plus LABAs versus
ICs alone were considered. Where adjusted ORs were
not reported, unadjusted ORs were held. To assess the
risk of severe exacerbation in patients with asthma
treated with LABAs plus ICs, compared to those treated
only with ICs, meta-analyses were carried out for indi-
vidual specific adverse events and combined outcomes.
Subgroup analyses for children and administration mode
were planned. The summary OR and 95% CI estimated
in the meta-analyses, together with ORs from individual
studies, were presented in forest plots.
Heterogeneity among studies was evaluated using
Galbraith plot and I2 statistic categorized as follows: <30%
not important; 30%-50% moderate; 50%-75% substantial;
and 75%-100% considerable [19]. If significant heterogen-
eity was identified among studies, further examination of
the individual studies was conducted, and random effects
models (Dersimonian-Laird Method) were used to obtain
the summary OR estimates. Otherwise, fixed effects
models were used (Mantel-Haentzel Method). Publication
bias was assessed by Egger regression asymmetry test and
funnel plots. The meta-analytic software program used
was STATA.12.
Results
Literature search results
The literature search identified 4,415 articles (Figure 1).
After excluding 195 duplicates, 4,220 titles and 1,759
Figure 1 Flow chart diagram.
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most frequent reason for exclusion during title and ab-
stract review was “did not apply to any key question”
(25.2%), and “other publication type” (42%), respectively;
and during full text review, presenting “other study de-
signs” (31.4%) or evaluating “other treatments” (31.4%).
Detailed reasons for excluding manuscripts at each step
are displayed in Additional file 1. Seventeen of the po-
tentially relevant articles were excluded after full text
reading (characteristics are shown in Additional file 1).
Finally, 19 studies met the inclusion criteria.
Characteristics of included studies
Main characteristics of included studies are displayed in
Table 1. The majority (16/19) were retrospective obser-
vational cohorts based on pharmacy claims from insur-
ance databases. These studies analysed patients with
asthma who had initiated an inhaled treatment with
LABAs plus ICs or ICs alone. There was also 1 prospect-
ive observational cohort, 1 case-control study and 1before-after study. All the articles described studies car-
ried out in either USA (16/19) or UK (3/19). Regarding
sample size, number of participants varied from 50
(Nguyen WT et al. 2005) [20] to 514,216 (Guo JJ et al.
2011) [21]. All articles included have been approved by
their Ethics Committee
Assessment of risk of bias in individual studies
An overview of the risk of bias in individual studies is
shown in Figure 2. First, all studies compared the
LABAs plus ICs group with the ICs alone group, as this
was an inclusion criterion. Therefore, risk of bias in this
item was not identified. Second, risk related to allocation
was intermediate since patients were allocated by treat-
ment decisions and not by location differences, partici-
pant’s preferences, or based on outcomes. Third, we
considered the risk related to retrospective design as inter-
mediate, because the outcomes assessment was retro-
spective and the generation of hypothesis was prospective.
Fourth, risk of bias related to groups’ comparability was
Table 1 Characteristics of included studies
Author and
publication year
Study
design
Sample
size (n)
Age
(years)
Administration
mode
Follow-up
period
Ascertainment of
asthma
Outcomes Endpoint
measureSpecific Combined
Wells et al., 2012 [22] RC 1,828 12-56 Single inhaler *2.1(2.0) years Asthma treatment ————— 1- Asthma-related hospitalization OR
asthma-related ED visit OR Systemic
Corticosteroid use
aHR
Jacobs et al., 2012 [23] C-C 181 4-18 Not stated NA Clinical diagnosis 1- ICU admission ————— aOR OR
2- Deaths
3- Intubation
4- Positive air pressure use
Stanford et al., 2012 [24] RC 10,837 65-79 Single inhaler 12 months Claims for asthma 1- Asthma-related
hospitalization
1- Asthma-related hospitalization OR
asthma-related ED visits
aHR
2- Asthma-related ED visits
3- Systemic Corticosteroid
use
Guo et al., 2011 [21] RC 514,216 0-40 Single & Separate
inhalers
- Claims for asthma ————— 1- Asthma-related hospitalization OR
asthma-related ED visits OR Asthma-related
intubations
aHR
Stanford et al., 2010 [25] RC 50,428 > 4 Single inhaler *290.4 (102.8)
days
Claims for asthma 1- Asthma-related
hospitalization
1- Asthma-related hospitalization OR
asthma-related ED visits
aHR
2- Asthma-related ED visits
Hagiwara et al., 2010 [26] RC 894 12-64 Single inhaler 3-12 months Claims for asthma 1-Asthma-related
hospitalization
1- Hospitalization OR ED visits aOR
2-Asthma-related ED visits 2- Hospitalization OR ED visits OR
Systemic Corticosteroid use
3-Use of SABAs
Delea et al., 2010 [27] RC 1,744 > 12 Single inhaler 3-12 months Claims for asthma 1- ED visits 1- ED visits OR Hospitalization aOR
2- ED visits OR hospitalization OR
Systemic Corticosteroid use
de Vries et al., 2010 [28] RC 467,639 >18 Not stated 5 years Claims for asthma 1- All mortality; ————— aRR
2- Asthma-related mortality
3-Asthma-related
hospitalization
4-GP visits for exacerbation
Lee et al., 2010 [29] RC 28,074 18-56 Single & Separate
inhalers
12 months Claims for asthma 1- Asthma-related
hospitalization
————— OR
2-Asthma-related ED visits
3-Systemic Corticosteroid
use
4- SABAs use
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Table 1 Characteristics of included studies (Continued)
Thomas et al., 2009 [30] RC 64,348 10-58 Single & Separate
inhalers
12 months Claims for asthma
and asthma
treatment
1- Respiratory
Hospitalization
1- Asthma-related hospitalization OR
asthma-related ED visits OR > 2 prescription
of Systemic Corticosteroid uses OR
SABA prescription
aOR
2- Systemic Corticosteroid
use
3- SABAs use
Stanford et al., 2008 [31] RC 58,270 > 12 Single inhaler 12 months Claim for asthma 1-Asthma-related
Hospitalization
1- Asthma-related ED visits OR
asthma-related Hospitalization
aOR
2- Asthma-related ED visits aHR
Campbell et al., 2008 [32] PC 684 > 18 Single inhaler 24 months Severe asthma ————— 1- Asthma-related hospitalization OR
asthma-related ED visit OR Systemic
Corticosteroid use
aOR OR
Colice et al., 2008 [33] RC 1,283 6-64 Not stated 12 months Claims for asthma 1- Asthma-related
hospitalization
————— OR
2- Asthma-related ED visits
Delea et al., 2008 [34] RC 2,269 > 5 Single & Separate
inhalers
12 months Claims for asthma 1- Asthma-related
hospitalization
1- Asthma-related hospitalization OR ED
visits OR Systemic Corticosteroid use OR
alternative study medication
aOR
2- Asthma-related ED visits 2- Asthma-related hospitalizations OR ED
visits OR oral corticosteroid
3- Oral corticosteroids use 3- Asthma-related hospitalization OR ED
visits hospitalization
Friedman et al., 2007 [35] RC 5,503 12-65 Single inhaler 12 months Claims for asthma 1-Asthma-related
hospitalization
————— aOR
2-Asthma-related ED visits
3- Any ED visits
Zhang et al., 2007 [36] RC 2,596 15-55 Single & Separate
inhalers
12 months Claims for asthma 1- Oral corticosteroid use 1- Asthma-related hospitalization OR
asthma-related ED visits
OR
2- SABA use
Stempel et al., 2006 [37] RC 9,192 4-17 Single inhaler 12 months Claims for asthma 1- SABA use 1- Asthma-related hospitalization OR
asthma-related ED visit
aRR
2-Corticosteroids use
O’Connor et al., 2005 [38] RC 2,414 > 15 Single & Separate
inhalers
12 months Claims for asthma ————— 1- Asthma-related hospitalization OR ED
visits
aOR aHR
Nguyen et al., 2005 [20] B-A 50 4-17 Single inhaler 12 months Enrolled patients 1- Asthma-related
hospitalization
————— aRR
2- Asthma-related ED
visits
RC: Retrospective Cohort; C-C: Case-control study; PC: Prospective cohort; B-A: Before-after study; * = Mean (SD); SABA = Short- Acting Beta-Agonist; ED = Emergency Department; HR = Hazard Ratio; OR = Odds Ratio;
aHR = Adjusted HR; aOR = Adjusted OR.
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Figure 2 Risk of bias assessment in individual studies.
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for potential confounders and studies compared outcome
variables at baseline. Only the study of Colice et al. [33]
had not done either of these two procedures (red mark on
Figure 2).
Meta-analyses results
Of the 19 studies identified, 6 were not included in the
meta-analyses performed (4 retrospective cohorts, the
case-control, and the before-after study) because they
did not provide any of the specific estimators assessed.The most commonly reported outcomes were emergency
department (ED) visit and asthma-related hospitalization
(reported in 9 and 8 studies, respectively), followed by sys-
temic corticosteroid use (4 studies). There were also two
commonly combined outcomes: asthma-related hospitali-
zations, asthma-related ED visits or systemic corticoster-
oid (5 studies); and asthma-related hospitalizations or
asthma-related ED visits (9 studies). The latter meta-
analysis was not reported because it presented consider-
able heterogeneity (I2 = 93%).
Subgroup analyses concerning age and administration
mode (single or separate inhalers) could not be per-
formed due to the lack of studies providing disaggre-
gated information for these groups. The three studies
focused on children and adolescents had different de-
signs (case-control, before-after and retrospective), and
only two of the four retrospective cohorts which in-
cluded adults and children stratified their analysis by age
subgroups. Regarding administration mode, 10 studies
included only users of fixed-dose LABAs plus ICs in a
single inhaler, three studies did not provide this informa-
tion, and only three of the six studies which included
LABAs plus ICs both as single or two separate inhalers
performed disaggregate analysis (Guo et al. [21], Delea
et al. [34], and O’Connor et al. [38]).
Asthma-related hospitalizations
Figure 3 shows the Forest plot (Figure 3a), Galbraith plot
(Figure 3b), and Funnel plot (Figure 3c) of the asthma-
related hospitalization meta-analysis. Estimators of this
outcome were provided by 8 of the retrospective co-
horts. Overall, these studies included 624,303 patients.
Results from the study by Delea et al. [34] were included
as 2 different estimators because specific ORs for single
and separate inhalers (instead of an overall OR) were
provided. The ORs of the individual studies ranged from
0.72 (95% CI 0.55-0.95) reported by Stanford et al. [24]
to 4.52 (95% CI 0.28-72.53) reported by Delea et al. [34].
The summary OR was 0.88 (95% CI 0.69-1.12). Random
effect models were used due to substantial heterogeneity
(I2 = 66%). The Galbraith plot (Figure 3b) showed that
all points except the study corresponding to deVries
et al. [28] fell within the confidence limits. However, this
has a considerable weight due to the large sample size
(n = 467,639). The Funnel plot (Figure 3c) seems sym-
metric and Egger’s test was non-significant, which sug-
gests that there was no publication bias.
Asthma-related ED visits
The forest plot of the risk of asthma-related ED visits
was constructed from 9 studies including 153,799 pa-
tients (Figure 4). All the ORs of the individual studies
were lower than 1 and the overall summary OR was 0.75
(95% CI 0.66-0.84). A fixed effect model was used
Forest plot
Galbraith plot
Funnel plot
Figure 3 This figure includes Forest plot (a), Galbraith plot (b), and Funnel plot (c) of the asthma-related hospitalization meta-analysis.
Figure 4 This figure includes Forest plot (a), Galbraith plot (b), and Funnel plot (c) of the asthma-related emergency department visits.
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showed that most studies fell within the confidence limits,
and the Funnel plot suggested no publication bias.
Asthma-related systemic corticosteroid use
Four studies (105,855 patients in total) provided estima-
tors of asthma-related systemic corticosteroid use risk
(Figure 5). Results from the study by Thomas et al. [30]
were included as four separate estimators because ORs
were provided for each age group. The summary OR
was 1.02 (95% CI 0.94-1.10), calculated with a fixed ef-
fects model as no heterogeneity was found. All studies
fell inside the confidence limits of Galbraith plot, and
the funnel plot appeared symmetric.
Combined outcome of asthma-related hospitalizations,
asthma-related ED visits or systemic corticosteroid use
Data from 5 studies were available for severe asthma
exacerbations meta-analysis (Figure 6), defined as
asthma-related hospitalizations, asthma-related ED visits
or systemic corticosteroid use. Overall, these studies in-
cluded 69,939 patients and the summary OR was 0.95
(95% CI 0.9-1). Results from the study by Campbell
et al. [32] were included as two separate estimators be-
cause ORs were provided for both low and high cortico-
steroid doses. The latter is the only individual estimatorFigure 5 This figure includes Forest plot (a), Galbraith plot (b), and Fuabove 1 (OR = 1.42; 95% CI 0.92-2.19). A random effects
model was used, as substantial heterogeneity was found
(I2 = 70%). Figure 6b shows that estimators provided by
Campbell et al. [32], Hagiwara et al. [26], and Delea
et al. [34] fell just outside the confidence limits. Simi-
larly, three estimators are placed outside the triangle in
the funnel plot. As there are only 5 studies included in
this meta-analyses, Egger’s test cannot be interpreted.Discussion
To date, less than 10% of all systematic reviews have ad-
verse events’ assessment as a primary objective [39]. Our
findings support the relevance and suitability of perform-
ing systematic reviews of harms to provide valuable infor-
mation on these risks. This systematic review identified 19
studies which met the inclusion criteria: 16 retrospective
cohorts, 1 prospective cohort, 1 case-control, and 1
before-after study (1,165,342 participants). The meta-
analyses performed (69,939-624,303 participants accord-
ing to the outcome considered) showed that the LABAs/
ICs combined treatment was not associated to a higher
risk of adverse events, when compared with ICs alone.
The OR ranged from 0.75 to 1.02 for the different out-
comes explored, which is congruent with findings from
meta-analyses of RCTs assessing asthma-related seriousnnel plot (c) of the asthma-related systemic corticosteroid use.
Figure 6 This figure includes Forest plot (a), Galbraith plot (b), and Funnel plot (c) of the asthma-related hospitalization or emergency
department visits or systemic corticosteroid use.
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and formoterol (0.53; 95% CI 0.28-1.0) [10].
This consistency between our results and those from
meta-analyses of RCTs reinforces the evidence available
on this topic. It is well known that RCTs are the gold
standard in evaluating efficacy and safety of emerging
therapies. However, their poor external validity [40] is a
particular concern for long term chronic conditions that
affect large and heterogeneous patient populations, such
as asthmatics. In fact, it has been estimated that only
1.2% [41] or 5% [42] of the usual care asthma population
could have been eligible for a typical asthma RCT. In this
context, despite potential issues regarding observational
studies’ internal validity, they are gaining widespread rec-
ognition [43,44] providing valuable information on treat-
ment effectiveness and safety, especially in long-term
outcomes.
To our knowledge, this is the first systematic review of
non-randomized studies including children and adults
with asthma to assess adverse events of LABAs, as the
only systematic review of observational studies previ-
ously published was limited to adult patients (asthma-re-
lated hospitalizations OR = 0.85; 96%CI 0.74-0.97) [17].
It included mainly unpublished studies identified from a
pharmaceutical company’s research register. Since then,
the publication of 12 observational studies permitted theinclusion of a larger number of patients. In comparison
with systematic reviews of salmeterol and formoterol
RCTs (with 15,309 and 13,366 patients, respectively),
synthesis of non-randomized studies provides results
from larger representative asthma samples, more accurate
reflection of the usual clinical practice, and longer follow-
up periods. The follow-up periods of studies included in
our systematic review ranged from 3 months to 5 years,
being in most cases 1 year (12 studies), an adequate frame
of time for the assessment of adverse events [19].
We identified several limitations on our review process.
First, four retrospective cohorts could not be included in
any of the meta-analyses performed due mainly to the lack
of the specific estimator needed, but their results were
consistent with our findings [21,22,37,38]. Second, out-
comes of these retrospective cohorts varied substantially,
from systemic corticosteroids use to deaths. Related to this
wide range of clinical outcomes, there was a limitation for
synthesizing them by meta-analysis – mortality, a primary
outcome of interest, was reported only by one study [28].
Furthermore, the use of composite endpoints could give
misleading conclusions because the components have dif-
ferent relevance [45]. However, not only the composite
endpoints, but also the individual adverse events which
compose them have been considered in the meta-analyses.
Third, internal validity of the summary provided by a
Hernández et al. Respiratory Research 2014, 15:83 Page 10 of 12
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Confounding and selection bias could distort the findings
from observational studies and therefore meta-analyses in-
cluding them would produce biased estimates also. In our
systematic review, sensitivity analysis by quality assess-
ment was not performed as risk of bias was homogeneous
among studies. Quality assessment was considered moder-
ate for most of them because the studies were mainly
comparative, allocation was based on treatment decisions,
and adjusted by potential confounders. In fact, only few
unadjusted estimators were included in the meta-analysis,
and the sensitivity analyses carried out to assess the im-
pact of excluding them, showed similar summary ORs:
0.89 (95% CI 0.69-1.15) for asthma-related hospitalization
and 0.75 (95% CI 0.67-0.85) for asthma-related ED visits.
Most of the retrospective cohort studies identified in
this systematic review obtained data from administrative
medical claims and electronic health records, with defini-
tions based on medication prescriptions and ICD-9 diag-
nosis (i.e. asthma codes for inclusion and other respiratory
conditions for exclusion). The main limitations derived
from designs of this nature include: a) presence of a pre-
scription claim does not necessarily indicate that the medi-
cation was taken; and b) asthma severity criteria were not
applied in most studies, and in those that did, severity defi-
nitions were based on medication use instead of spirometry
or clinical parameters. To balance treatment groups, most
of the studies made adjustments on baseline risk factors
and socioeconomic variables by using regression models
and propensity score matching. Nevertheless, possible con-
founding factors such as severity and adherence could still
remain.
The planned subgroup analysis for children and ad-
ministration mode (as single or two separate inhalers)
could not be conducted, and merits further comments.
Stanford et al. [25] performed an analysis stratified by
age groups with similar results for adults and children
aged 4-18 years: OR was 0.917 (95% CI 0.85-0.98) for
ED visit and 0.88 (95% CI 0.7-1.11) for hospitalization.
The case-control study by Jacobs et al. [23] showed that
paediatric LABA use in combination with ICs did not
increase the likelihood of intensive care unit admission
among hospitalized children, compared to ICs alone. Re-
garding administration mode, the little available evidence
is controversial. The largest retrospective cohort identi-
fied in this review [21] is remarkable because it showed
higher risk for single inhalers compared with separate
inhalers on a combined outcome composed of asthma-
related hospitalizations, intubations or asthma-related
ED visits: OR of 1.13 (95% CI 1.09-1.16) among newly
diagnosed patients, and OR of 1.12 (95% CI 1.10-1.12)
among those with pre-existing asthma. On the contrary,
in the study by O’Connor et al. [38] patients receiving
LABAs plus ICs in a single inhaler were less likely to havean ED visit or to be hospitalized, compared with patients
receiving the same treatment in separate inhalers (OR
0.69, 95% CI 0.51-.95). Delea et al. [34] showed similar re-
sults in both administration modes.
Heterogeneity was substantial (66.5% and 70.5%) in two
of the four meta-analyses reported. In those conducted
with asthma-related hospitalization risk, the only study out
of the confidence limits in the Galbraith plot was deVries
et al. [28]. This study differs from the other ones in having
a follow-up period of 5 years, but many other possible rea-
sons could explain such heterogeneity. In the meta-
analysis conducted with the combined outcome, the only
estimator that fell outside the Galbraith plot limits was the
group with high dose of corticosteroids and salmeterol in
Campbell et al. [32], with an OR higher than 1. This might
reflect that despite the adjustments, patients taking high
corticosteroid doses represented a more severe group.
Almost two thirds of the studies were performed by
Glaxo Smith Kline Beecham, while others received in-
dustry support without describing the extent of involve-
ment of their sponsors. Usually, publication bias refers
to the journals’ rejection of studies with negative results.
Yet safety studies sponsored by the pharmaceutical in-
dustry could suffer from publication bias in the opposite
direction, as it is more likely to publish negative results
and to select the most favourable outcomes. We have
found no evidence of publication bias in the meta-
analyses reported, but Egger’s test has limited power
when the number of studies is low, and funnel plots may
have subjective interpretation.
Conclusions
The current evidence from non-randomized studies shows
that combined treatment of LABAs and ICs is not associ-
ated with higher risk of serious adverse events. Our system-
atic review identified major gaps in the available literature;
accordingly our key recommendations for further research
are to conduct prospective cohort studies, to perform
studies among the paediatric population, and to include
mortality as a primary outcome. Accumulative valid data is
needed to allow evidence-based decisions taking into
account safety of LABAs plus ICs in asthma treatment.
Additional file
Additional file 1: The additional file contains the search strategy,
the inclusion and exclusion criteria, the risk of bias assessment tool
and information regarding the articles excluded at each step of the
Systematic Review.
Abbreviations
ICs: Inhaled corticosteroids; LABAs: Long-acting beta2–agonists; SABAs: Short
acting beta agonists; RCT: Randomized clinical trial; FDA: Federal Drug
Administration; ED: Emergency department; ICU: Intensive care unit
admissions; CI: Confidence intervals; HR: Hazard ratio.
Hernández et al. Respiratory Research 2014, 15:83 Page 11 of 12
http://respiratory-research.com/content/15/1/83Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
GH contributed to the conception and design of the article, conceptualized and
oversaw analyses, contributed to the interpretation of data, and wrote the
article. MA contributed to the reviewing and web search of included and
excluded articles. AP contributed to the analysis and gave statistical support. OG,
JA, CC, LL oversaw all aspects and reviewed the article for important intellectual
content. MF oversaw all aspects, contributed to the conception and design of
the article, contributed to the statistical analyses, carried out the interpretation
of data, and contributed to the writing of the article. All the co-authors critically
revised the manuscript and approved the final draft before submission.
Acknowledgments
We would like to thank A. Martin (IMIM Hospital del Mar Medical Research
Institute) for the English review and editing of the manuscript.
Members of the ASTRO-LAB group are: Marijn De Bruin, Alexandra Dima
(ASCoR, University of Amsterdam, The Netherlands); Eric Van Ganse, Laurent
Laforest, Sandrine Herbage, Manon Belhassen, Marine Ginoux (LBBE, University
Claude Bernard Lyon 1, France); Stéphane Schück, Nathalie Texier, Sandy
Leproust, Hélène Le Cloarec (Kappa Santé, France); Richard Hubbard (University
of Nottingham, England); Alison Bourke, Mary Thompson , Delphine Vial, David
Ansell (Cegedim Strategic Data, England); Javier Olaiz, Ana Valcarcel Orti (Lyon
Ingénierie Projet, France) ; and Montse Ferrer, Olatz Garin, Gimena Hernández
(IMIM - Hospital del Mar Medical Research Institute, Spain).
Fundings
Financial support for this study was provided by the Health Research Fund
(European Union FP7, ASTROLAB project EC HEALTH-F5-2011-282593); the
Agency for Management of University and Research Grants AGAUR
(2012FI_B1 00177); and a Fundación Carolina Fellowship. The funding
agreement ensures the authors’ independence in designing the study,
interpreting the data, and writing and publishing the report. None of these
organizations had any role in the design or conduction of the study, nor in
the data collection, management or interpretation, nor in the manuscript
writing, reviewing, or approval.
Author details
1Health Services Research Group. IMIM (Hospital del Mar Medical Research
Institute), Barcelona Biomedical Research Park, office 144. Doctor Aiguader,
88 | 08003, Barcelona, Spain. 2Universitat Autònoma de Barcelona, Bellaterra,
Spain. 3CIBER en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain.
4Pompeu Fabra University (UPF), Barcelona, Spain. 5UCBL Unité de
Pharmacoépidémiologie - UMR 5558 CNRS - Université Claude Bernard, Lyon,
France. 6St George’s University of London, Population Health Sciences and
Education, London, UK.
Received: 15 April 2014 Accepted: 14 July 2014
Published: 19 July 2014
References
1. Walters EH, Gibson PG, Lasserson TJ, Walters JA: Long-acting beta2-
agonists for chronic asthma in adults and children where background
therapy contains varied or no inhaled corticosteroid. Cochrane Database
Syst Rev 2007, 1:1–340.
2. Castle W, Fuller R, Hall J, Palmer J: Serevent nationwide surveillance study:
comparison of salmeterol with salbutamol in asthmatic patients who
require regular bronchodilator treatment. BMJ 1993, 306:1034–1037.
3. Levenson M: Long-acting beta-agonists and adverse asthma events
meta-analysis: Briefing package for joint meeting of the Pulmonary-
Allergy Drug Advisory Committee and Pediatric Advisory Committee on
December 10-11, 2008. 2012, Available from URL: http://www.fda.gov/
ohrms/dockets/ac/08/briefing/2008-4398b1-01-FDA.pdf [cited 2012 Oct 4].
4. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM: The Salmeterol
Multicenter Asthma Research Trial: a comparison of usual
pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
Chest 2006, 129:15–26.
5. Cates CJ, Cates MJ: Regular treatment with formoterol for chronic asthma:
serious adverse events. Cochrane Database Syst Rev 2012, 4, CD006923.6. Weatherall M, Wijesinghe M, Perrin K, Harwood M, Beasley R: Meta-analysis
of the risk of mortality with salmeterol and the effect of concomitant
inhaled corticosteroid therapy. Thorax 2010, 65:39–43.
7. Jaeschke R, O’Byrne PM, Mejza F, Nair P, Lesniak W, Brozek J, Thabane L, Cheng J,
Schunemann HJ, Sears MR, Guyatt G: The safety of long-acting beta-agonists
among patients with asthma using inhaled corticosteroids: systematic review
and metaanalysis. Am J Respir Crit Care Med 2008, 178:1009–1016.
8. Cates CJ, Jaeschke R, Schmidt S, Ferrer M: Regular treatment with
salmeterol and inhaled steroids for chronic asthma: serious adverse
events. Cochrane Database Syst Rev 2013, 3:1–79.
9. Bateman E, Nelson H, Bousquet J, Kral K, Sutton L, Ortega H, Yancey S:
Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on
serious asthma-related events. Ann Intern Med 2008, 149:33–42.
10. Cates CJ, Jaeschke R, Schmidt S, Ferrer M: Regular treatment with
formoterol and inhaled steroids for chronic asthma: serious adverse
events. Cochrane Database Syst Rev 2013, 6:1–82.
11. Salpeter SR: An update on the safety of long-acting beta-agonists in asthma
patients using inhaled corticosteroids. Expert Opin Drug Saf 2010, 9:407–419.
12. Lipworth BJ: Long-acting beta2-adrenoceptor agonists: a smart choice for
asthma? Trends Pharmacol Sci 2007, 28:257–262.
13. Chowdhury BA, Dal PG: The FDA and safe use of long-acting beta-
agonists in the treatment of asthma. N Engl J Med 2010, 362:1169–1171.
14. Sears MR: Safety of long-acting beta-agonists: are new data really
required? Chest 2009, 136:604–607.
15. Beasley R, Perrin K, Weatherall M, Wijesinghe M: Call for withdrawal of
LABA single-therapy inhaler in asthma. Lancet 2010, 376:750–751.
16. Wijesinghe M, Perrin K, Harwood M, Weatherall M, Beasley R: The risk of
asthma mortality with inhaled long acting beta-agonists. Postgrad Med J
2008, 84:467–472.
17. Hirst C, Calingaert B, Stanford R, Castellsague J: Use of long-acting beta-
agonists and inhaled steroids in asthma: meta-analysis of observational
studies. J Asthma 2010, 47:439–446.
18. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale
TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HA, Lazarus SC,
Levy ML, O'Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW,
Sullivan SD, Szefler SJ, Thomas MD, Wenzel SE: An official American Thoracic
Society/European Respiratory Society statement: asthma control and
exacerbations: standardizing endpoints for clinical asthma trials and clinical
practice. Am J Respir Crit Care Med 2009, 180:59–99.
19. Cochrane Group: Cochrane handbook for systematic reviews of
interventions-Version 5.1. 2012, Available from URL: http://www.cochrane-
handbook.org/. [Cited 2012, October 11].
20. Nguyen WT, Stewart C, Fisher K, Tolley E, Lew DB, Self TH: Maintenance
asthma treatment with fluticasone/salmeterol combination via Diskus:
effect on outcomes in inner-city children enrolled in TennCare.
Allergy Asthma Proc 2005, 26:129–134.
21. Guo JJ, Tsai K, Kelton CM, Bian B, Wigle PR: Risk of serious asthma
exacerbations associated with long-acting beta agonists among patients
with asthma: a retrospective cohort study. Ann Allergy Asthma Immunol
2011, 106:214–222.
22. Wells KE, Peterson EL, Ahmedani BK, Severson RK, Gleason-Comstock J,
Williams LK: The relationship between combination inhaled corticosteroid
and long-acting beta-agonist use and severe asthma exacerbations in a
diverse population. J Allergy Clin Immunol 2012, 129:1274–1279.
23. Jacobs TS, Jones BL, MacGinnitie AJ: Long-acting beta-agonists and the risk
of intensive care unit admission in children. J Asthma 2012, 49:450–455.
24. Stanford RH, Blanchette CM, Roberts MH, Petersen H, Fuhlbrigge AL: Effect
of combination fluticasone propionate and salmeterol or inhaled
corticosteroids on asthma-related outcomes in a Medicare-eligible
population. Am J Geriatr Pharmacother 2012, 10:343–351.
25. Stanford RH, Riedel AA, Johnson JC, Astry CL: Comparative resource
utilization in medicaid-eligible patients with asthma treated with fixed-
dose fluticasone propionate/salmeterol or fluticasone propionate
monotherapy. Clin Ther 2010, 32:1782–1793.
26. Hagiwara M, Delea TE, Stanford RH, Stempel DA: Stepping down to
fluticasone propionate or a lower dose of fluticasone propionate/
salmeterol combination in asthma patients recently initiating
combination therapy. Allergy Asthma Proc 2010, 31:203–210.
27. Delea TE, Hagiwara M, Stempel DA, Stanford RH: Adding salmeterol to
fluticasone propionate or increasing the dose of fluticasone propionate
in patients with asthma. Allergy Asthma Proc 2010, 31:211–218.
Hernández et al. Respiratory Research 2014, 15:83 Page 12 of 12
http://respiratory-research.com/content/15/1/8328. De VF, Setakis E, Zhang B, van Staa TP: Long-acting {beta}2-agonists in
adult asthma and the pattern of risk of death and severe asthma
outcomes: a study using the GPRD. Eur Respir J 2010, 36:494–502.
29. Lee TA, Chang CL, Stephenson JJ, Sajjan SG, Maiese EM, Everett S, Allen-Ramey F:
Impact of asthma controller medications on medical and economic resource
utilization in adult asthma patients. Curr Med Res Opin 2010, 26:2851–2860.
30. Thomas M, Von ZJ, Lee AJ, Price D: High-dose inhaled corticosteroids
versus add-on long-acting beta-agonists in asthma: an observational
study. J Allergy Clin Immunol 2009, 123:116–121.
31. Stanford RH, Fuhlbrigge A, Riedel A, Rey GG, Stempel DA: An observational
study of fixed dose combination fluticasone propionate/salmeterol or
fluticasone propionate alone on asthma-related outcomes. Curr Med Res
Opin 2008, 24:3141–3148.
32. Campbell JD, Borish L, Haselkorn T, Rasouliyan L, Lee JH, Wenzel SE, Sullivan
SD: The response to combination therapy treatment regimens in severe/
difficult-to-treat asthma. Eur Respir J 2008, 32:1237–1242.
33. Colice GL, Yu AP, Ivanova JI, Hsieh M, Birnbaum HG, Lage MJ, Brewster C:
Costs and resource use of mild persistent asthma patients initiated on
controller therapy. J Asthma 2008, 45:293–299.
34. Delea TE, Hagiwara M, Stanford RH, Stempel DA: Effects of fluticasone
propionate/salmeterol combination on asthma-related health care
resource utilization and costs and adherence in children and adults with
asthma. Clin Ther 2008, 30:560–571.
35. Friedman HS, Yawn BP: Resource utilization in asthma: combined
fluticasone propionate/salmeterol compared with inhaled
corticosteroids. Curr Med Res Opin 2007, 23:427–434.
36. Zhang Q, Thomas M, Wisniewski T, Sazonov KV, Price D: Treatment and
outcomes in patients with asthma and allergic rhinitis in the United
kingdom. Int Arch Allergy Immunol 2007, 142:318–328.
37. Stempel DA, Riedel AA, Carranza Rosenzweig JR: Resource utilization with
fluticasone propionate and salmeterol in a single inhaler compared with
other controller therapies in children with asthma. Curr Med Res Opin
2006, 22:463–470.
38. O’Connor RD, Rosenzweig JR, Stanford RH, Gilmore AS, Ryskina KL, Legorreta
AP, Stempel DA: Asthma-related exacerbations, therapy switching, and
therapy discontinuation: a comparison of 3 commonly used controller
regimens. Ann Allergy Asthma Immunol 2005, 95:535–540.
39. Zorzela L, Golder S, Liu Y, Pilkington K, Hartling L, Joffe A, Loke Y, Vohra S:
Quality of reporting in systematic reviews of adverse events: systematic
review. BMJ 2014, 348:f7668.
40. Rothwell PM: External validity of randomised controlled trials: “to whom
do the results of this trial apply?”. Lancet 2005, 365:82–93.
41. Herland K, Akselsen JP, Skjonsberg OH, Bjermer L: How representative are
clinical study patients with asthma or COPD for a larger “real life” population
of patients with obstructive lung disease? Respir Med 2005, 99:11–19.
42. Travers J, Marsh S, Williams M, Weatherall M, Caldwell B, Shirtcliffe P, Aldington
S, Beasley R: External validity of randomised controlled trials in asthma: to
whom do the results of the trials apply? Thorax 2007, 62:219–223.
43. Concato J, Shah N, Horwitz RI: Randomized, controlled trials,
observational studies, and the hierarchy of research designs. N Engl J
Med 2000, 342:1887–1892.
44. Hernan MA, Alonso A, Logan R, Grodstein F, Michels KB, Willett WC, Manson
JE, Robins JM: Observational studies analyzed like randomized
experiments: an application to postmenopausal hormone therapy and
coronary heart disease. Epidemiology 2008, 19:766–779.
45. Ferreira-Gonzalez I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM,
Alonso-Coello P, Alonso J, Worster A, Upadhye S, Jaeschke R, Schunemann HJ,
Permanyer-Miralda G, Pacheco-Huergo V, Domingo-Salvany A, Wu P, Mills EJ,
Guyatt GH: Problems with use of composite end points in cardiovascular
trials: systematic review of randomised controlled trials. BMJ 2007, 334:786.
doi:10.1186/1465-9921-15-83
Cite this article as: Hernández et al.: Long-acting beta-agonists plus
inhaled corticosteroids safety: a systematic review and meta-analysis of
non-randomized studies. Respiratory Research 2014 15:83.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
